Trend of CD4 Cell Count at Initiation of Highly Active Antiretroviral Therapy (HAART) in Klinik Kesihatan Seremban (KKS)

Nur Zafirah; K. Y. Gan; Payal Choudhury; A.B. Nabila Farhana; B. Shahnaz

Nur Zafirah Pharmacy Department, Seremban Health Clinic, Seremban Health District Office, Negeri Sembilan State Health Department, Malaysia
K. Y. Gan Pharmacy Department, Seremban Health Clinic, Seremban Health District Office, Negeri Sembilan State Health Department, Malaysia
Payal Choudhury Pharmacy Department, Seremban Health Clinic, Seremban Health District Office, Negeri Sembilan State Health Department, Malaysia
A.B. Nabila Farhana Pharmacy Department, Seremban Health Clinic, Seremban Health District Office, Negeri Sembilan State Health Department, Malaysia
B. Shahnaz Pharmacy Department, Seremban Health Clinic, Seremban Health District Office, Negeri Sembilan State Health Department, Malaysia

Abstract

Background: CD4 T lymphocyte (CD4) is the most important marker that has been used in the management of HIV. The CD4 cell count provides information on the overall immune function of an HIV-infected patient. There is an overwhelming evidence that early initiation of HAART, at higher CD4 cell count will lead to virological and immunological success, prevent disease progression and reduces the social and economic costs of advanced HIV-related illness. We investigated the trend of CD4 cell count at initiation of HAART among HIV patients in KKS.

Materials and Method: All registered HIV patients from year 2012 to 2017 were enrolled in this study. Data was collected retrospectively from patient’s data base and clinic’s registry using a standardized data collection form. The data was analyzed by using SPSS version 16.0 and presented with percentages, mean and median values. We also compared the CD4 cell count at HAART initiation with recommendation in Malaysian Consensus Guideline on Antiretroviral. Additionally, we investigated the possible factors that lead to late initiation of HAART.

Results: Mean and median values of CD4 cell count at initiation of HAART were 411.03 cell/mm³and 314 cell/mm³respectively. There was an increasing trend of median CD4 cell count from 2014 until 2016 and in reducing trend in 2017. From 41 patients who were initiated on HAART, 68.3% (n=28) initiated HAART early while 31.7% (n=13) had late initiation. The late initiation of HAART was primarily due to late presenters.

Conclusion: CD4 cell count at initiation of HAART in KKS was found to be high. Generally the practice of initiating HAART in KKS is in compliance to the Malaysian Consensus Guideline in ART. However, a number of patients with late initiation of HAART is of concern. We recommend a strategic interventions to increase earlier detection of HIV patients and earlier start of HAART at higher CD4 cell count to prevent HIV transmission and improve mortality and morbidity.

NMRR ID : NMRR-17-2098-37774

Keywords: CD4, Antiretroviral, T lymphocyte, HIV

Downloads

Download data is not yet available.

References

Asfaw, A., Ali, D., Eticha, T., Alemayehu, A., Alemayehu, M., Kindeya, F. (2015). CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. PLoS One. 10:e0122583.
Braunstein, S. L., Robertson, M. M., Myers, J., Abraham, B., Nash, D. (2016). Increase in CD4+ T-Cell Count at the Time of HIV diagnosis and antiretroviral treatment initiation among persons with HIV in New York city. The Journal of Infectious Diseases, 214:(11). 1682–1686.
Delpech, V., Brown, A. E., Croxford, S., Chau, C., Polavarapu, V., Cooper, N., Rooney, G. Yin, Z. (2013). Quality of HIV care in the United Kingdom: key indicators for the first 12 months from HIV diagnosis. HIV Medicine, 14 (Suppl. 3), 19–24.
Department of Health and Human Services (HHS).(2018). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-in¬fected adults and adolescents. https://aidsinfo.nih.gov/guidelines.
European AIDS Clinical Society. (EACS).(2017). Guidelines for the Clinical. Management and Treatment of HIV Infected Adults in Europe. EACS Guidelines 9.0. 10-14.
Global AIDS Response Progress Report 2016.
Insight Start Study Group, Lundgren, J. D., Babiker, A. G. et. al. (2015). Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 373. 795–807.
Jeong, S. J., Italiano, C., Chaiwarith, R., Ng, O. T., Vanar, S., Jiamsakul, A., … Choi, J. Y. (2016). Late Presentation into Care of HIV Disease and Its Associated Factors in Asia: Results of TAHOD. AIDS Research and Human Retroviruses, 32(3), 255–261. http://doi.org/10.1089/aid.2015.0058
Kiertiburanakul, S., Boettiger, D., Lee, M. P., Omar, S. F., Tanuma, J., Ng, O. T., … Sungkanuparph, S. (2014). Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. Journal of the International AIDS Society, 17(1), 18804. http://doi.org/10.7448/IAS.17.1.18804
Kim MJ, et al. (2017). Trend of CD4+ Cell Counts at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea HIV/AIDS Cohort Study, 1992-2015. Infect Chemother; 49(2).101-108.
Koh Kwee Choy (2017). Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Ministry of Health Malaysia.
Kumar, M., Kumar, R., Mahdi, A. A., Dhole, T. N. (2017). Study of Viral Load and CD4 Count in Diagnosis of HIV-1 Positive Patients. J Fam Med. 4(4). 1117.
Raffetti, Elena et al. (2016). The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health. 16. 878.
Shen, Y., Wang, J., Qi, T., Wang, Z., Lu, H. (2013) Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011. Int J STD AIDS, 25. 504-10.
WHO (2015). Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization, Geneva. Available from: https://www.ncbi.nlm.nih.gov/books/NBK327115/
Yamashita, T. E., Phair, J. P., Muñoz, A., Margolick, J. B., Detels, R., O'Brien, S. J., Mellors, J. W., Wolinsky, S. M., Jacobson, L. P. (2001) Immu¬nologic and virologic response to highly active antiretrovi¬ral therapy in the Multicenter AIDS Cohort Study. AIDS. 15, 735-46.